#Endocrine | #GrowthHormone | #Metabolic

CJC-1295 (No DAC) — Modified GHRH 1-29

CJC-1295 (No DAC), also frequently referred to in literature as Modified GRF 1-29, is a synthetic analogue of the endogenous Growth Hormone Releasing Hormone (GHRH). It is modified with four amino acid substitutions to enhance resistance to enzymatic cleavage, allowing for sustained investigation of pituitary GHRH receptor stimulation without the rapid degradation seen with native GHRH.

Compound Name

CJC-1295 (No DAC)

Synonyms

Mod GRF 1-29, Tetrasubstituted GHRH

Sequence Length

29 Amino Acids

Target

GHRH Receptor (Pituitary)

Sequence

YADAXFXQSYRKVLAQLSARKLLQDXLSR

Molecular Weight

~3367.9 g/mol

Molecular Formula

C₁₅₂H₂₅₂N₄₄O₄₂

Store powder at +4°C (short term) or -20°C (long term). Keep desiccated.

Sterile bacteriostatic water. Preparation should be performed under aseptic conditions. Reconstituted material is not intended for long-term storage.

Molecular Formula

Overview & Mechanism of Action

CJC-1295 (No DAC) binds to the GHRH receptor on the somatotroph cells of the anterior pituitary gland. This binding activates the cAMP signaling pathway, leading to the pulsatile release of Growth Hormone (GH).

The “No DAC” designation indicates the absence of the Drug Affinity Complex (a maleimidopropionic acid linker attached to a lysine residue). Without this complex, the peptide does not bind covalently to serum albumin, resulting in a half-life of approximately 30 minutes in humans—significantly longer than native GHRH (<5 minutes) but much shorter than CJC-1295 with DAC (several days). This shorter half-life is preferred in research models where mimicking natural pulsatile secretion is the goal.

Research Applications

Pulsatile Secretion Models: Used to mimic physiological GH spikes without inducing continuous elevation that can lead to receptor downregulation.
Synergy Studies: Frequently co-administered with GHRPs (e.g., Ipamorelin) to investigate synergistic effects on somatotroph depolarization and hormone release.
Metabolic Analysis: Investigating downstream effects of GH pulses on lipolysis and protein synthesis in animal models.

Dosage & Administration (Experimental)

Experimental design varies by study objective; literature highlights the following pharmacokinetic considerations:

Pulsatility: Mimicking natural GH pulse timing is critical to avoid pituitary desensitization. Continuous exposure often leads to downregulated receptor sensitivity.
Half-life Considerations: Absence of the drug affinity complex creates a defined activity window, often requiring frequency adjustments compared to native GHRH.
Synergistic Co-administration: Often paired with GHRPs to evaluate non-linear amplification of somatotroph response, affecting exposure calculations in experimental designs.

Safety & Side Effects (Research Context)

In preclinical models, excessive stimulation of the GHRH axis can lead to:

Hyperglycemia or insulin resistance (diabetogenic effect of GH)
Water retention and tissue edema
Potential pituitary desensitization if administered continuously rather than in pulses

Key Scientific References

Teichman, S. L., et al. (2006) “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295.” Journal of Clinical Endocrinology & Metabolism.
Alba, M., et al. (2006) “Once-daily administration of CJC-1295… normalizes growth in the GHRH knockout mouse.” American Journal of Physiology.
PubChem. CJC-1295 without DAC. National Center for Biotechnology Information.

The compound listed below is referenced in research contexts related to the mechanisms discussed in this article.

The compound CJC-1295 (No DAC) discussed on this page is a chemical reference standard intended strictly for in-vitro and laboratory research applications (e.g., receptor binding assays, cell culture studies). It is not a drug, dietary supplement, or food additive. It is not intended for human consumption, injection, or therapeutic use. All handling must be performed by qualified professionals in a laboratory setting.

CJC-1295 (No DAC) — Modified GHRH 1-29

Compound Name

Synonyms

Sequence Length

Target

Sequence

Molecular Weight

Molecular Formula

Molecular Formula

Age Verification Required

NAD+ Buffered

MOTS-c

KPV

KLOW Blend

Ipamorelin

HGH Fragment 176-191

Glutathione

GLOW Blend

GHK-Cu